Analysis finds oncology trials may lack rigor

05/7/2013 | PharmaTimes (U.K.)

An analysis of nearly 9,000 clinical trials of cancer therapies conducted between 2007 and 2010 found the trials tend to be smaller and less robust than trials for therapies in other disease areas. The Duke University analysis was part of the FDA's Clinical Trials Transformation Initiative to improve the quality and efficiency of clinical trials. Oncology trials tended to be small, early-stage and nonrandomized, researchers reported in JAMA Internal Medicine.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA